- Home
- TCMD vs LRMR Comparison
TCMD vs LRMR Comparison
Compare TCMD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | LRMR |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.2M | 455.8M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TCMD | LRMR |
|---|---|---|
| Price | $21.82 | $3.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $36.00 | $16.50 |
| AVG Volume (30 Days) | 366.6K | ★ 911.9K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.14 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $9.14 | $1,816.14 |
| P/E Ratio | $85.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.14 | $2.72 |
| 52 Week High | $37.77 | $6.42 |
Technical Indicators
Market Signals| Indicator | TCMD | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 41.98 |
| Support Level | $20.53 | $3.49 |
| Resistance Level | $26.49 | $4.21 |
| Average True Range (ATR) | 0.88 | 0.18 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 14.26 | 2.31 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.